BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $51 from $52 and keeps a Buy rating on the shares. The firm updated its model to reflect flatter expectations for growth in PKD and slightly reduced 2025 thalassemia expectations given the company should only book a partial quarter of revenues, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharma Appoints Dr. Jay Backstrom as Director
- Agios Pharmaceuticals appoints Jay Backstrom to board
- Agios Pharma Increases Shares in Stock Incentive Plan
- Agios Pharma’s Strategic Partnerships and Promising Drug Developments Drive Buy Rating
- Agios Pharmaceuticals price target lowered to $56 from $61 at H.C. Wainwright